EL7.AI
StocksMediumUpdated•Originally published 30 June 2026•Updated 30 June 2026•
1 min read

Abivax Surges 25% on Positive Ulcerative Colitis Drug Data

Key Facts

1Abivax's obefazimod showed positive clinical trial results for ulcerative colitis, driving the stock price up 25%.
2BTIG analyst set a price target of $175 for Abivax, implying 82% upside from $96.15.
3Maintenance study showed 37.2% of patients achieved clinical remission at 44 weeks, with malignancy rates in line with background levels.

In a move reflecting positive momentum for the biotech sector, shares of Abivax surged 25% after the company announced positive results for its drug obefazimod in ulcerative colitis. A maintenance study showed 37.2% of patients achieved clinical remission at 44 weeks, with malignancy rates in line with background levels, alleviating prior safety concerns.

According to reports, the stock rose from $96.15 to around $120 following the announcement, giving the company a market cap of $6.3 billion. A BTIG analyst set a $175 price target, implying 82% upside from the pre-announcement close. The data confirmed the drug's efficacy in maintaining clinical remission with an acceptable safety profile.

As of the close on June 30, 2026, the stock trades near $120, with attention now on upcoming regulatory steps and further trial readouts. The $175 price target could act as a catalyst for investors, though trading volumes and any additional clinical disclosures warrant close monitoring.

Latest Updates · 1

  1. Major·

    Update: On July 1, 2026, Abivax announced a public offering of American Depositary Shares (ADS) worth approximately $600 million. The offering could dilute existing shareholders and pressured the stock in early trading. Investors await pricing details and the impact on the company's capital structure.